• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Argentina Formally Starts Producing Russia’s Sputnik Covid-19 Vaccine

firstwordpharmaJune 07, 2021

Tag: COVID-19 , Vaccine , Sputnik V

Argentina and Russia's president formally announced that a pharmaceutical company in the South American nation will start producing the Sputnik V COVID-19 vaccine, Bloomberg reported.

Argentina Formally Starts Producing Russia’s Sputnik Covid-19 Vaccine

Presidents Vladimir Putin and Alberto Fernandez said production will start at Laboratorios Richmond SA in Buenos Aires.

Argentina has received 8.9 million Sputnik V doses this year, accounting for nearly half of its total vaccines.

Previous:Phase II clinical trial of Niclosamide drug for treatment of COVID-19 patients begins

Next:South Korea's IP laws key to expanding COVID-19 vaccine partnership: US senators

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Argentina Formally Starts Producing Russia’s Sputnik Covid-19 Vaccine | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Influenza Vaccine in 2022

Influenza Vaccine in 2022
Ruminant Vaccine Series

Ruminant Vaccine Series
Hualan BIO Influenza Vaccine (Split virion)

Hualan BIO Influenza Vaccine (Split virion)
Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological 1

Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological 1
Hualan- Influenza Vaccine

Hualan- Influenza Vaccine
Influenza Vaccine in Syringe

Influenza Vaccine in Syringe
Hualan Biological Meningococcal Polysaccharide Vaccine Group ACYW135

Hualan Biological Meningococcal Polysaccharide Vaccine Group ACYW135
High quality of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

High quality of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
Hualan‘s Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

Hualan‘s Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
Hualan Biological Influenza Vaccine(Split Virion),Inactivated

Hualan Biological Influenza Vaccine(Split Virion),Inactivated

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service